BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29146058)

  • 1. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas.
    Kardum V; Karin V; Glibo M; Skrtic A; Martic TN; Ibisevic N; Skenderi F; Vranic S; Serman L
    Ann Diagn Pathol; 2017 Dec; 31():45-49. PubMed ID: 29146058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
    Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
    Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
    Shih YL; Shyu RY; Hsieh CB; Lai HC; Liu KY; Chu TY; Lin YW
    Cancer; 2006 Aug; 107(3):579-90. PubMed ID: 16795071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight into the role of PTCH1 protein in serous ovarian carcinomas.
    Karin-Kujundzic V; Covarrubias-Pinto A; Skrtic A; Vranic S; Serman L
    Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36205138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor.
    Qi J; Zhu YQ; Luo J; Tao WH
    World J Gastroenterol; 2006 Nov; 12(44):7113-7. PubMed ID: 17131472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation-associated silencing of SFRP1 in renal cell carcinoma.
    Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
    Oncol Rep; 2008 Nov; 20(5):1257-63. PubMed ID: 18949430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.
    Qiu X; Klausen C; Cheng JC; Leung PC
    Cell Death Dis; 2015 Aug; 6(8):e1864. PubMed ID: 26313915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells.
    Wu Y; Li J; Sun CY; Zhou Y; Zhao YF; Zhang SJ
    Neoplasma; 2012; 59(3):326-32. PubMed ID: 22296502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal Carcinoma.
    Kumar A; Gosipatala SB; Pandey A; Singh P
    Asian Pac J Cancer Prev; 2019 May; 20(5):1571-1577. PubMed ID: 31128064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
    Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
    Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.
    Kaur P; Mani S; Cros MP; Scoazec JY; Chemin I; Hainaut P; Herceg Z
    Tumour Biol; 2012 Apr; 33(2):325-36. PubMed ID: 22351518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dishevelled family proteins in serous ovarian carcinomas: a clinicopathologic and molecular study.
    Karin-Kujundzic V; Kardum V; Sola IM; Paic F; Skrtic A; Skenderi F; Serman A; Nikuseva-Martic T; Vranic S; Serman L
    APMIS; 2020 Mar; 128(3):201-210. PubMed ID: 31755579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.
    Rogler A; Kendziorra E; Giedl J; Stoehr C; Taubert H; Goebell PJ; Wullich B; Stöckle M; Lehmann J; Petsch S; Hartmann A; Stoehr R
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1779-90. PubMed ID: 25732201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.